Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Simcor niacin/simvastatin: Phase III data

In the double-blind Phase III SEACOAST trial in >600 patients, Simcor met the primary endpoint of a significant reduction in non-HDL cholesterol vs. simvastatin alone. The study compared 1,000 mg of Niaspan

Read the full 326 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE